Valassi Elena, Chiodini Iacopo, Feelders Richard A, Andela Cornelie D, Abou-Hanna Margueritta, Idres Sarah, Tabarin Antoine
Endocrinology Department, Germans Trias i Pujol Hospital and Research Institute, Badalona, Barcelona, Spain.
IRCCS, Istituto Auxologico Italiano, Milan, Italy.
Endocr Connect. 2022 Jun 24;11(7). doi: 10.1530/EC-22-0027. Print 2022 Jul 1.
Cushing's syndrome (CS) is a rare condition of chronically elevated cortisol levels resulting in diverse comorbidities, many of which endure beyond successful treatment affecting the quality of life. Few data are available concerning patients' experiences of diagnosis, care and persistent comorbidities.
To assess CS patients' perspectives on the diagnostic and care journey to identify unmet therapeutic needs.
A 12-item questionnaire was circulated in 2019 by the World Association for Pituitary Organisations. A parallel, 13-item questionnaire assessing physician perceptions on CS patient experiences was performed.
Three hundred twenty CS patients from 30 countries completed the questionnaire; 54% were aged 35-54 and 88% were female; 41% were in disease remission. The most burdensome symptom was obesity/weight gain (75%). For 49% of patients, time to diagnosis was over 2 years. Following treatment, 88.4% of patients reported ongoing symptoms including, fatigue (66.3%), muscle weakness (48.8%) and obesity/weight gain (41.9%). Comparisons with delay in diagnosis were significant for weight gain (P = 0.008) and decreased libido (P = 0.03). Forty physicians completed the parallel questionnaire which showed that generally, physicians poorly estimated the prevalence of comorbidities, particularly initial and persistent cognitive impairment. Only a minority of persistent comorbidities (occurrence in 1.3-66.3%; specialist treatment in 1.3-29.4%) were managed by specialists other than endocrinologists. 63% of patients were satisfied with treatment.
This study confirms the delay in diagnosing CS. The high prevalence of persistent comorbidities following remission and differences in perceptions of health between patients and physicians highlight a probable deficiency in effective multidisciplinary management for CS comorbidities.
库欣综合征(CS)是一种罕见疾病,其皮质醇水平长期升高,会导致多种合并症,其中许多在成功治疗后仍会持续存在,影响生活质量。关于患者在诊断、护理及持续性合并症方面的经历,现有数据较少。
评估库欣综合征患者对诊断和护理过程的看法,以确定未满足的治疗需求。
2019年,垂体组织世界协会发放了一份包含12个条目的问卷。同时进行了一份包含13个条目的平行问卷,以评估医生对库欣综合征患者经历的看法。
来自30个国家的320名库欣综合征患者完成了问卷;54%的患者年龄在35至54岁之间,88%为女性;41%的患者疾病处于缓解期。最困扰患者的症状是肥胖/体重增加(75%)。49%的患者诊断时间超过2年。治疗后,88.4%的患者报告仍有症状,包括疲劳(66.3%)、肌肉无力(48.8%)和肥胖/体重增加(41.9%)。体重增加(P = 0.008)和性欲减退(P = 0.03)与诊断延迟的比较具有显著性。40名医生完成了平行问卷,结果显示,总体而言,医生对合并症的患病率估计不足,尤其是初始和持续性认知障碍。除内分泌科医生外,只有少数持续性合并症(发生率为1.3%至66.3%;专科治疗率为1.3%至29.4%)由其他专科医生处理。63%的患者对治疗感到满意。
本研究证实了库欣综合征诊断存在延迟。缓解后持续性合并症的高患病率以及患者与医生对健康认知的差异,凸显了库欣综合征合并症有效多学科管理可能存在不足。